Ji-long Yang-Jilong

Key Laboratory Of Cancer Prevention And Therapy Of Tianjin, State Key Laboratory Of Druggability Evaluation And Systematic Translational Medicine
Tianjin, 300060, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Retrospective cohort study on pedicled flap reconstruction after trunk soft tissue sarcoma resection: Surgical outcomes and survival analysis.

Retrospective cohort study on pedicled flap reconstruction after trunk soft tissue sarcoma resection: Surgical outcomes and survival analysis.

Journal: Journal of plastic, reconstructive & aesthetic surgery : JPRAS

Published: July 28, 2025

Anti-PD-1 antibody plus anlotinib vs. anlotinib alone in patients with refractory chondrosarcoma: A multicenter, non-randomized phase 2 FLAIL-C trial.

Anti-PD-1 antibody plus anlotinib vs. anlotinib alone in patients with refractory chondrosarcoma: A multicenter, non-randomized phase 2 FLAIL-C trial.

Journal: Med (New York, N.Y.)

Published: June 05, 2025

A multicenter study of neurofibromatosis type 1 utilizing deep learning for whole body tumor identification.

A multicenter study of neurofibromatosis type 1 utilizing deep learning for whole body tumor identification.

Journal: NPJ digital medicine

Published: February 23, 2024

The fusion gene LRP1-SNRNP25 drives invasion and migration by activating the pJNK/37LRP/MMP2 signaling pathway in osteosarcoma.

The fusion gene LRP1-SNRNP25 drives invasion and migration by activating the pJNK/37LRP/MMP2 signaling pathway in osteosarcoma.

Journal: Cell death discovery

Published: December 02, 2023

Efficacy of salvage therapies after failure of adjuvant anti-PD-1 monotherapy for melanoma in the Chinese population: a multi-institutional cohort study.

Efficacy of salvage therapies after failure of adjuvant anti-PD-1 monotherapy for melanoma in the Chinese population: a multi-institutional cohort study.

Journal: Investigational new drugs

Published: November 06, 2022

Retraction Note: Genomic amplification and high expression of EGFR are key targetable oncogenic events in malignant peripheral nerve sheath tumor.

Retraction Note: Genomic amplification and high expression of EGFR are key targetable oncogenic events in malignant peripheral nerve sheath tumor.

Journal: Journal of hematology & oncology

Published: October 28, 2022

Landscape of enhancer disruption and functional screen in melanoma cells.

Landscape of enhancer disruption and functional screen in melanoma cells.

Journal: Genome biology

Published: August 18, 2022

A single-cell analysis reveals tumor heterogeneity and immune environment of acral melanoma.

A single-cell analysis reveals tumor heterogeneity and immune environment of acral melanoma.

Journal: Nature communications

Published: July 09, 2021

Outcomes of surgery and/or combination chemotherapy for extraskeletal osteosarcoma: a single-center retrospective study from China.

Outcomes of surgery and/or combination chemotherapy for extraskeletal osteosarcoma: a single-center retrospective study from China.

Journal: Scientific reports

Published: November 14, 2018

Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety.

Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety.

Journal: Experimental & molecular medicine

Published: September 20, 2018

Histone deacetylase 6 in cancer.

Histone deacetylase 6 in cancer.

Journal: Journal of hematology & oncology

Published: July 10, 2018

The prognostic value of C-X-C motif chemokine receptor 4 in patients with sporadic malignant peripheral nerve sheath tumors.

The prognostic value of C-X-C motif chemokine receptor 4 in patients with sporadic malignant peripheral nerve sheath tumors.

Journal: Chinese journal of cancer

Published: November 30, 2016

Showing 1-12 of 22

Last Updated: 09/26/2026